BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Covagen Nominates Frank Walsh as Executive Chairman and Appoints Mathias Locher as Chief Development Officer


3/7/2011 10:37:01 AM

Zürich-Schlieren, Switzerland, March 7th, 2011 -- Covagen announced today the nomination of Prof. Frank Walsh as its new Executive Chairman of the Board and the appointment of Dr. Mathias Locher as Chief Development Officer. Frank Walsh is currently CEO of the biotechnology company Ossianix Inc. (Philadelphia, USA). He has more than 15 years experience as a senior executive in the pharmaceutical industry. Between 2002 - 2009 he worked for Wyeth (Collegeville PA, USA), where he last served as Executive Vice President and Head of Discovery Research Worldwide. He led more than 1500 scientists across seven sites globally and managed an annual budget of USD 360 million. Prior to joining Wyeth, Frank Walsh was at GlaxoSmithKline (UK) where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery. From 1997 - 2000 he was Vice President and Head of Neuroscience Research at SmithKline Beecham (UK). Before moving to industry, Frank Walsh had a distinguished academic career, during which he authored over 200 scientific publications in his roles as the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas’ Hospitals (London, UK), and as the Sir William Dunn Professor of Experimental Pathology. Frank Walsh received his B.Sc. in biochemistry from the University of Strathclyde (Glasgow, Scotland) and holds a Ph.D. from University College in London (UK).

Commenting on his nomination, Frank Walsh stated: “I am impressed by the versatility of the Fynomer technology platform and I am genuinely looking forward to contribute to the further development of this exciting company.”

Mathias Locher brings with him more than 20 years experience in pharmaceutical development of drugs, with a focus on protein-based therapeutics. From 2007 - 2011, he served as Global Head of Drug Metabolism and Pharmacokinetics (DMPK) at MerckSerono (Geneva, Switzerland). Mathias Locher led a team of about 145 FTE across five sites globally. Prior to this he served for four years as Vice President of Preclinical Development at Micromet Inc. (Munich, Germany). There he was accountable for the entire preclinical development of the bispecific BiTE proteins as well as monoclonal antibodies. Mathias Locher holds a Ph.D. in biochemistry from the University of Tuebingen (Germany).

Mathias Locher said, “I am very excited to join Covagen and I look forward to contribute to the creation of a strong Fynomer portfolio of clinical product candidates.”

Julian Bertschinger, Covagen’s CEO added, “We are very pleased to have gained Frank as our new Executive Chairman and to have strengthened Covagen’s management team with Mathias Locher. Frank and Mathias bring with them extensive knowledge of business and pharmaceutical development which will be tremendously valuable to lead Covagen forward towards the next stage of its evolution.”

For further details, please contact:

Covagen AG Dr. Julian Bertschinger, CEO Tel: +41 (0) 44 732 46 60 julian.bertschinger@covagen.com

About Covagen:

Covagen commercializes next generation protein drugs for the treatment of inflammatory diseases and cancer by using its proprietary protein engineering technology, which has been developed at ETH Zurich (Switzerland). Covagen's innovative platform comprises a novel single domain protein scaffold, which - in analogy to antibodies - can be engineered to yield high affinity binding proteins called Fynomers that can be used for therapeutic applications. The possibility to create bispecific as well as multivalent Fynomers and their favorable biophysical properties allow for treatment modalities that are difficult or impossible to be exploited with antibodies.



Read at BioSpace.com

Covagen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES